Literature DB >> 27741013

Factors Influencing Progression of Keratoconus 2 Years After Corneal Collagen Cross-Linking in Pediatric Patients.

Ozge Sarac1, Mehtap Caglayan, Hasan Basri Cakmak, Nurullah Cagil.   

Abstract

PURPOSE: To assess the preoperative patient characteristics that may predict outcomes of keratoconus 2 years after corneal collagen cross-linking (CXL) in pediatric patients with keratoconus.
METHODS: This retrospective study included 72 eyes of 52 consecutive patients with keratoconus under the age of 18 with 2-year follow-up after CXL. Subgroup analysis and cutoff values were determined as per age (<14 and ≥14 years), sex, baseline uncorrected and corrected distance visual acuities (UCVA, CDVA; <0.8 and ≥0.8 logMAR), topographic cone location (central and paracentral), maximum keratometry (K-max, <54 and ≥54 diopters), and corneal thickness at the thinnest point (thCT) (<450 and ≥450 μm) to evaluate the associations between preoperative patient characteristics and outcomes of CXL treatment in terms of K-max. Postoperative progression in K-max was defined as steepening of 1.0 diopter or more.
RESULTS: Average age of patients was 14.8 ± 2.2 (9-17) years. After 2 years, the mean UCVA significantly improved and the mean thCT significantly decreased in all patients (P = 0.023, P < 0.001, respectively). The K-max in patients with paracentral cones and/or with thCT less than 450 μm were more likely to progress (cone location: P = 0.023, odds ratio = 3.21, 95% confidence interval, 1.17-8.72; thCT: P = 0.008, odds ratio = 4.54, 95% confidence interval, 1.46-14.14). Age, sex, baseline UCVA, CDVA, and K-max did not present any significant effect on progression of CXL after treatment (P > 0.05 for all variables).
CONCLUSIONS: In pediatric patients with keratoconus, cone location and the baseline thinnest corneal thickness seem to affect the success rate of CXL treatment after 2-year follow-up.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27741013     DOI: 10.1097/ICO.0000000000001051

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  8 in total

1.  Three-year follow-up of accelerated versus standard corneal cross-linking in paediatric Keratoconus.

Authors:  Biana Dubinsky-Pertzov; Boris Knyazer; Adi Einan-Lifshitz; Asaf Achiron; Shira Hed; Idan Hecht
Journal:  Eye (Lond)       Date:  2022-05-19       Impact factor: 3.775

Review 2.  Pediatric keratoconus: a review of the literature.

Authors:  Sabrina Mukhtar; Balamurali K Ambati
Journal:  Int Ophthalmol       Date:  2017-08-29       Impact factor: 2.031

Review 3.  Corneal Cross-Linking for Pediatric Keratcoconus Review.

Authors:  Claudia Perez-Straziota; Ronald N Gaster; Yaron S Rabinowitz
Journal:  Cornea       Date:  2018-06       Impact factor: 2.651

4.  Predictive factors of the accelerated transepithelial corneal cross-linking outcomes in keratoconus.

Authors:  Mi Tian; Weijun Jian; Xiaoyu Zhang; Ling Sun; Yang Shen; Xingtao Zhou
Journal:  BMC Ophthalmol       Date:  2022-01-03       Impact factor: 2.209

5.  The Effect of Cone Localization on Higher Order Aberrations After Corneal Crosslinking for Keratoconus.

Authors:  Nilay Kandemir Besek; Gulay Yalcinkaya; Ahmet Kirgiz; Fevziye Ondes Yilmaz; Burcin Kepez Yildiz; Yusuf Yildirim; Ahmet Demirok
Journal:  Beyoglu Eye J       Date:  2021-09-27

Review 6.  Pediatric Crosslinking: Current Protocols and Approach.

Authors:  Júlia Polido; Maria Emília Dos Xavier Santos Araújo; João G Alexander; Thiago Cabral; Renato Ambrósio; Denise Freitas
Journal:  Ophthalmol Ther       Date:  2022-04-28

Review 7.  Complications of corneal collagen cross-linking.

Authors:  Richa Agarwal; Parul Jain; Ritu Arora
Journal:  Indian J Ophthalmol       Date:  2022-05       Impact factor: 2.969

8.  Long-Term Visual, Refractive and Topographic Outcomes of "Epi-off" Corneal Collagen Cross-Linking in Pediatric Keratoconus: Standard versus Accelerated Protocol.

Authors:  Ibrahim Amer; Abdelhakeem Elaskary; Ali Mostafa; Hazem A Hazem; Ahmed Omar; Ahmed Abdou
Journal:  Clin Ophthalmol       Date:  2020-11-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.